UK appoints first clinical director for informatics
This article was originally published in Scrip
The UK's Department of Health has appointed its first national clinical director for informatics, Charles Gutteridge. Mr Gutteridge, who is a fellow of the Royal College of Physicians and previously chaired the Association of UK University Hospitals Medical Directors, will lead in liaising with clinicians to ensure that informatics, such as computer science, provides critical and responsive services to patient care. The role is initially for a two-year period. At the end of last year, Mr Gutteridge stepped down from his role as medical director at Barts and The London Trust, where he had worked since 2002; he will take up his new clinical director role this month.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).